Alzheimer’s startup Alzheon bags $10M and beats a path to Phase III

The veteran Alzheimer’s researchers at Alzheon believe their novel treatment for the disease has a chance to come through where so many others have failed.  Alzheon’s drug targets beta amyloid proteins, buildups in the brain widely believed to contribute to the disease’s neurodegenerative effects. But unlike the slew of high-profile–and largely failed–antibody treatments, Alzheon’s candidate is an oral tablet designed to interrupt the formation of beta amyloid before the proteins have a chance to damage brain tissues and destroy memory.

As quoted from fiercebiotech.com.  Read the full article here
2016-12-06T09:24:17+00:00 April 8th, 2015|Tags: |